Drugs / Trivalent Influenza Vaccine
Trivalent Influenza Vaccine
Trials 17
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01941758 | Nov 2013 → Nov 2014 | central nervous system neoplasm | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 1 | NCT01695733 | Sep 2011 → Sep 2013 | neoplasm | Washington University School of Medicine | Terminated | No outcome recorded Stop: Business |
| Phase 24 trials · 1 met primary | ||||||
| Phase 2 | NCT03179761 | Oct 2017 → Feb 2022 | disease related to hematopoietic stem cell transplant | Vanderbilt-Ingram Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT02860039 | Sep 2016 → Dec 2021 | cancer, disease related to hematopoietic stem cell transplant, influenza | Vanderbilt-Ingram Cancer Center | Completed | Met primary |
| Phase 2 | NCT02518555 | Jan 2016 → Dec 2025 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Jennifer Woyach | Completed | No outcome recorded |
| Phase 2 | NCT00956202 | Aug 2009 → Sep 2010 | swine influenza | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 48 trials · 1 met primary | ||||||
| Phase 4 | NCT06252051 | Jan 2021 → Mar 2022 | chronic kidney disease, diabetes mellitus, influenza | Padjadjaran University | Completed | No outcome recorded |
| Phase 4 | NCT04080531 | Oct 2019 → May 2021 | plasma cell neoplasm | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT02882100 | Apr 2016 → Oct 2018 | influenza | Insight Therapeutics, LLC | Completed | Met primary |
| Phase 4 | NCT02473510 | Jun 2015 → Jan 2016 | influenza | MedImmune LLC | Completed | No outcome recorded |
| Phase 4 | NCT01816464 | Sep 2013 → Feb 2014 | influenza | University of Witwatersrand, South Africa | Completed | No outcome recorded |
| Phase 4 | NCT01859143 | May → Dec 2013 | influenza | MedImmune LLC | Completed | No outcome recorded |
| Phase 4 | NCT01863433 | May → Jun 2013 | influenza | Seqirus | Completed | No outcome recorded |
| Phase 4 | NCT00987350 | Jan → May 2010 | — | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT01561989 | Oct 2011 → Jul 2013 | — | Roswell Park Cancer Institute | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT01264601 | Oct 2010 → May 2012 | food allergy | University of Michigan | Completed | No outcome recorded |
| — | NCT00022035 | Aug 2000 → Nov 2002 | infectious disease, leukemia | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Comparator or background therapy8 trials | ||||||
| Phase 1 | NCT00848848 Comparator | Oct 2008 → Apr 2009 | influenza | Seqirus | Completed | No outcome recorded |
| Phase 1/2 | NCT02249221 Comparator | Oct → Nov 2014 | influenza | Green Cross Corporation | Completed | No outcome recorded |
| Phase 2 | NCT03336593 Comparator | Nov 2017 → Mar 2018 | — | PT Bio Farma | Completed | No outcome recorded |
| Phase 2/3 | NCT01306682 Comparator | Mar 2011 → Jun 2012 | influenza | University of Witwatersrand, South Africa | Completed | No outcome recorded |
| Phase 3 | NCT01481454 Comparator | Mar → Oct 2012 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
| Phase 3 | NCT01306669 Comparator | Mar 2011 → May 2013 | influenza | University of Witwatersrand, South Africa | Completed | No outcome recorded |
| Phase 4 | NCT02062281 Comparator | Nov → Dec 2013 | influenza, pneumococcal infection | Jiangsu Province Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 4 | NCT01246999 Comparator | Oct 2010 → Jan 2013 | influenza | University of Rochester | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 28 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trivalent Influenza Vaccine | “0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)” NCT00956202 ↗ |
| Known as | bioCSL Split Virion, Inactivated Influenza Vaccine | “A Phase IV, Single-Centre, Open-label Study to Evaluate the Immunogenicity and Safety of the 2013/2014 Formulation of a bioCSL Split Virion, Inactivated Influenza Vaccine in...” NCT01863433 ↗ |
| Known as | Enzira Vaccine | “A Study to Assess the Immunogenicity and Safety of a Trivalent Influenza Vaccine Containing the 2013/2014 Formulation of Enzira® Vaccine in Healthy Volunteers” NCT01863433 ↗ |
| Known as | HD-TIV | “We demonstrated in a primary phase 2 randomized controlled trial that 2 post-HCT doses of high-dose trivalent influenza vaccine (HD-TIV) given 4 weeks apart were more...” PMID 39279435 ↗ Feb 2025 |
| Known as | high-dose trivalent influenza vaccine | “We demonstrated in a primary phase 2 randomized controlled trial that 2 post-HCT doses of high-dose trivalent influenza vaccine (HD-TIV) given 4 weeks apart were more...” PMID 39279435 ↗ Feb 2025 |
| Known as | IIV3 | “METHODS: We conducted two double-blind, randomized, placebo-controlled trials of trivalent inactivated influenza vaccine (IIV3) in South Africa during 2011 in pregnant women...” PMID 25184864 ↗ Sep 2014 |
| Known as | TIV | “This randomized, placebo controlled trial will evaluate the safety and immunogenicity of Trivalent Influenza Vaccine (TIV) in HIV-infected pregnant women, dynamics of...” NCT01306682 ↗7“Single 0.5 ml 23-valent pneumococcal polysaccharide vaccine (23vPPV) and a single 0.5 ml trivalent inactivated influenza vaccine (TIV) were administered IM, in one day.” NCT02062281 ↗ “vaccination with either live trivalent influenza vaccine (LAIV) or trivalent influenza vaccine (TIV) in healthy children between the ages of 2 and 9 years.” NCT01246999 ↗ “Age appropriate dose of seasonal Trivalent Influenza Vaccine (TIV), either 0.25mL under age 3 or 0.5mL over the age of 3.” NCT01264601 ↗ “The seasonal flu vaccine that the researchers are using is called trivalent influenza vaccine (TIV).” NCT00987350 ↗ “0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)” NCT00956202 ↗ “Participants will receive the Trivalent Influenza Vaccine (TIV).” NCT01481454 ↗ “non-adjuvanted trivalent influenza vaccine (TIV) formulations” PMID 24732325 ↗ Apr 2014 |
| Known as | trivalent inactivated influenza vaccine | “METHODS: We conducted two double-blind, randomized, placebo-controlled trials of trivalent inactivated influenza vaccine (IIV3) in South Africa during 2011 in pregnant women...” PMID 25184864 ↗ Sep 2014 |
| Modality | Vaccine | “split-virus trivalent influenza vaccine” NCT00022035 ↗ |
| Route | Intramuscular | “trivalent influenza vaccine intramuscularly” NCT00022035 ↗ |